Lenvatol 4mg

Lenvatol is a medication used to treat certain types of cancer, including thyroid cancer, renal cell carcinoma, and endometrial cancer. It is an oral medication that works by inhibiting the growth of cancer cells.

Composition:

Lenvatol contains Lenvatinib, a medication that is a kinase inhibitor.

Indications:

Lenvatol is indicated for the treatment of:

1. Locally recurrent or metastatic thyroid cancer that has progressed following radioactive iodine treatment
2. Advanced renal cell carcinoma (RCC) in patients who have received prior VEGF-targeted therapy
3. Advanced endometrial cancer that has progressed following prior treatment with platinum-based chemotherapy

Mechanism of Action:

Lenvatinib works by:

1. Inhibiting the activity of multiple tyrosine kinases, including VEGFR, FGFR, and PDGFR
2. Reducing the production of vascular endothelial growth factor (VEGF) and other proangiogenic factors
3. Inhibiting the growth of cancer cells and blocking the formation of new blood vessels

Dosage and Administration:

The recommended dosage of Lenvatol is:

• 24mg taken orally once daily
• The dose should be taken with food and a glass of water
• The dose should be adjusted based on the patient’s response to treatment and tolerability

Side Effects:

Common side effects of Lenvatol include:

1. Diarrhea
2. Fatigue
3. Hypertension
4. Proteinuria
5. Nausea and vomiting
6. Abdominal pain
7. Headache

Serious side effects can include:

1. Gastrointestinal perforation or fistula
2. Severe bleeding
3. Cardiac failure
4. Respiratory problems
5. Hepatotoxicity

Contraindications:

Lenvatol is contraindicated in patients with:

1. Severe liver disease
2. Severe kidney disease
3. Pregnancy or breastfeeding
4. History of angioedema or other allergic reactions

Precautions:

1. Patients with a history of hypertension or cardiovascular disease should be closely monitored while receiving Lenvatol.
2. Patients with a history of kidney disease should be closely monitored while receiving Lenvatol.
3. Patients with a history of liver disease should be closely monitored while receiving Lenvatol.

Patient Counseling:

• Patients should be counseled on the importance of taking their medication as directed and not missing doses.
• Patients should be instructed to report any signs of diarrhea or other side effects.
• Patients should be advised to report any changes in their appetite or weight loss.

Storage and Handling:

• Store at room temperature (20°C to 25°C) and protected from light.
• Do not freeze or expose to direct sunlight.
• Use within 24 months of opening.

Please note that the dosage and administration information is based on the recommended dosage and may vary depending on individual patient needs and circumstances.